The Challenge of Intermediate-Risk Pulmonary Embolism

医学 肺栓塞 重症监护医学 心脏病学 内科学
作者
Spencer F. Weintraub,Joseph You,Sean R. Wilson,Andrew Galmer
出处
期刊:American Journal of Therapeutics 卷期号:30 (2): e134-e144 被引量:1
标识
DOI:10.1097/mjt.0000000000001605
摘要

Intermediate-risk pulmonary embolism is a common disease that is associated with significant morbidity and mortality; however, a standardized treatment protocol is not well-established.Treatments available for intermediate-risk pulmonary embolisms include anticoagulation, systemic thrombolytics, catheter-directed therapies, surgical embolectomy, and extracorporeal membrane oxygenation. Despite these options, there is no clear consensus on the optimal indication and timing of these interventions.Anticoagulation remains the cornerstone of treatment for pulmonary embolism; however, over the past 2 decades, there have been advances in the safety and efficacy of catheter-directed therapies. For massive pulmonary embolism, systemic thrombolytics and, sometimes, surgical thrombectomy are considered first-line treatments. Patients with intermediate-risk pulmonary embolism are at high risk of clinical deterioration; however, it is unclear whether anticoagulation alone is sufficient. The optimal treatment of intermediate-risk pulmonary embolism in the setting of hemodynamic stability with right heart strain present is not well-defined. Therapies such as catheter-directed thrombolysis and suction thrombectomy are being investigated given their potential to offload right ventricular strain. Several studies have recently evaluated catheter-directed thrombolysis and embolectomies and demonstrated the efficacy and safety of these interventions. Here, we review the literature on the management of intermediate-risk pulmonary embolisms and the evidence behind those interventions.There are many treatments available in the management of intermediate-risk pulmonary embolism. Although the current literature does not favor 1 treatment as superior, multiple studies have shown growing data to support catheter-directed therapies as potential options for these patients. Multidisciplinary pulmonary embolism response teams remain a key feature in improving the selection of advanced therapies and optimization of care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Berlin发布了新的文献求助10
3秒前
4秒前
grace0828发布了新的文献求助30
6秒前
大智关注了科研通微信公众号
9秒前
9秒前
蘅皋发布了新的文献求助10
10秒前
么嗷苗发布了新的文献求助30
11秒前
17完成签到 ,获得积分10
11秒前
PXD1986356457完成签到 ,获得积分10
12秒前
hui发布了新的文献求助10
12秒前
专注的清炎完成签到,获得积分20
13秒前
13秒前
ding应助文艺的小海豚采纳,获得10
16秒前
霄霄发布了新的文献求助10
16秒前
竹筏过海完成签到,获得积分0
17秒前
21秒前
无敌鱼发布了新的文献求助10
22秒前
23秒前
24秒前
24秒前
无花果应助summer采纳,获得100
25秒前
25秒前
鸳鸯士完成签到,获得积分10
26秒前
愤怒的白开水完成签到,获得积分10
26秒前
机灵若完成签到,获得积分10
27秒前
科研通AI2S应助学术智子采纳,获得10
27秒前
Rwmqwq完成签到,获得积分10
27秒前
热情笑旋完成签到,获得积分10
27秒前
29秒前
Hello应助科研通管家采纳,获得10
29秒前
桐桐应助科研通管家采纳,获得10
29秒前
30秒前
cctv18应助科研通管家采纳,获得10
30秒前
无花果应助科研通管家采纳,获得30
30秒前
搜集达人应助科研通管家采纳,获得10
30秒前
大智发布了新的文献求助10
30秒前
dcc发布了新的文献求助10
31秒前
甲木发布了新的文献求助10
32秒前
Owen应助无敌鱼采纳,获得10
32秒前
烟花应助米儿采纳,获得30
33秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The Three Stars Each: The Astrolabes and Related Texts 500
india-NATO Dialogue: Addressing International Security and Regional Challenges 400
A radiographic standard of reference for the growing knee 400
Epilepsy: A Comprehensive Textbook 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2470096
求助须知:如何正确求助?哪些是违规求助? 2137143
关于积分的说明 5445392
捐赠科研通 1861410
什么是DOI,文献DOI怎么找? 925756
版权声明 562721
科研通“疑难数据库(出版商)”最低求助积分说明 495201